

Stephen L Chan

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1915821/stephen-l-chan-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

212
papers

11,708
citations

51
h-index

106
g-index

261
ext. papers

15,673
ext. citations

5.8
avg. IF

6.24
L-index

#	Paper	IF	Citations
212	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 940-952	21.7	1120
211	Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. <i>Journal of Clinical Oncology</i> , 2015 , 33, 550-8	2.2	1097
210	Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2018 , 379, 54-63	59.2	1015
209	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 193-202 ²	2.2	600
208	Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E1317-25	11.5	392
207	Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E5503-12	11.5	391
206	Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. <i>Clinical Chemistry</i> , 2013 , 59, 211-24	5.5	373
205	Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer. <i>New England Journal of Medicine</i> , 2017 , 377, 513-522	59.2	338
204	Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1660-5	2.2	336
203	Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 18761-8	11.5	267
202	High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 177-82	2.2	242
201	New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. <i>Journal of Clinical Oncology</i> , 2009 , 27, 446-52	2.2	205
200	Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection. <i>Annals of Surgical Oncology</i> , 2015 , 22, 4138-48	3.1	162
199	Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3361-7	2.2	146
198	TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. <i>International Journal of Cancer</i> , 2009 , 124, 644-52	7.5	143
197	Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 875-886.e6	6.9	141
196	Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020 , 72, 307-319	13.4	133

195	Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. <i>Cancer Research</i> , 2013 , 73, 1676-88	10.1	127
194	Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. <i>British Journal of Cancer</i> , 2016 , 114, 744-50	8.7	119
193	Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4004-4004	2.2	118
192	Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. <i>Liver International</i> , 2019 , 39, 2214-2229	7.9	116
191	Infection and Cancer: The Case of Hepatitis B. <i>Journal of Clinical Oncology</i> , 2016 , 34, 83-90	2.2	105
190	Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. <i>World Journal of Gastroenterology</i> , 2016 , 22, 7289-300	5.6	96
189	A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. <i>Annals of Oncology</i> , 2012 , 23, 1287-1292	10.3	91
188	Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. <i>Annals of Oncology</i> , 2006 , 17, 1083-9	10.3	85
187	First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. <i>Cancer Discovery</i> , 2019 , 9, 1696-1707	24.4	85
186	The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas. <i>Laboratory Investigation</i> , 2007 , 87, 644-50	5.9	84
185	Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 1300-6	4	83
184	Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. <i>Genome Research</i> , 2019 , 29, 418-427	9.7	81
183	Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. <i>Annals of Oncology</i> , 2011 , 22, 1280-1287	10.3	77
182	A small-molecule modulator of the tumor-suppressor miR34a inhibits the growth of hepatocellular carcinoma. <i>Cancer Research</i> , 2014 , 74, 6236-47	10.1	76
181	Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016 , 65, 289-95	13.4	73
180	Phase I/II study of tamsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. <i>BMC Cancer</i> , 2015 , 15, 395	4.8	72
179	Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas. <i>Gastroenterology</i> , 2019 , 157, 1630-1645.e6	13.3	69
178	Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020 , 72, 320-341	13.4	68

177	Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2012 , 104, 300-4	5.3	68
176	A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2009 , 113, 529-35	4.4	65
175	Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011 , 26, 340-7	4	64
174	A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. <i>Liver Cancer</i> , 2020 , 9, 245-260	9.1	63
173	Targeted therapy of hepatocellular carcinoma: present and future. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012 , 27, 862-72	4	63
172	Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. <i>Gut</i> , 2020 , 69, 365-379	19.2	63
171	Albumin-to-alkaline phosphatase ratio: a novel prognostic index for hepatocellular carcinoma. <i>Disease Markers</i> , 2015 , 2015, 564057	3.2	62
170	Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. <i>Annals of Oncology</i> , 2015 , 26, 2457-63	10.3	62
169	Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma. <i>Histopathology</i> , 2014 , 64, 935-50	7.3	59
168	Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. <i>Hepatology</i> , 2016 , 64, 774-84	11.2	58
167	Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 1224-35	6.1	57
166	CircFOXK2 Promotes Growth and Metastasis of Pancreatic Ductal Adenocarcinoma by Complexing with RNA-Binding Proteins and Sponging MiR-942. <i>Cancer Research</i> , 2020 , 80, 2138-2149	10.1	56
165	Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. <i>Hepatology</i> , 2007 , 45, 1382-9	11.2	55
164	A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS4144-TPS4144	2.2	55
163	Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin. <i>Gastroenterology</i> , 2013 , 144, 1086-1097.e9	13.3	52
162	The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. <i>Investigational New Drugs</i> , 2010 , 28, 107-14	4.3	52
161	Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features. <i>Theranostics</i> , 2018 , 8, 1740-1751	12.1	51
160	Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 207-207	2.2	51

159	Systemic treatment of hepatocellular carcinoma: An EASL position paper. <i>Journal of Hepatology</i> , 2021 , 75, 960-974	13.4	49
158	Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma--correlation with excision repair cross-complementing-1 polymorphisms. <i>Annals of Oncology</i> , 2009 , 20, 1854-9	10.3	47
157	Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. <i>Hepatology</i> , 2020 , 72, 198-212	11.2	47
156	Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. <i>British Journal of Cancer</i> , 2017 , 116, 448-454	8.7	46
155	Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome. <i>American Journal of Surgical Pathology</i> , 2015 , 39, 304-12	6.7	46
154	Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?. <i>British Journal of Cancer</i> , 2018 , 118, 248-257	8.7	46
153	Personalized therapy for hepatocellular carcinoma: Where are we now?. <i>Cancer Treatment Reviews</i> , 2016 , 45, 77-86	14.4	45
152	A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. <i>Cancer</i> , 2012 , 118, 3984-92	6.4	43
151	Incorporating albumin-bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 221-228	4	39
150	Applicability of albumin-bilirubin-based Japan integrated staging score in hepatitis B-associated hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 1766-1772	4	39
149	Performance of serum α -fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. <i>Hpb</i> , 2014 , 16, 366-72	3.8	39
148	PARP inhibition in BRCA-mutated breast and ovarian cancers. <i>Lancet, The</i> , 2010 , 376, 211-3	40	38
147	Lymphedema and quality of life in Chinese women after treatment for breast cancer. <i>European Journal of Oncology Nursing</i> , 2009 , 13, 110-5	2.8	36
146	Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 379-379	2.2	36
145	Hong Kong consensus recommendations on the management of hepatocellular carcinoma. <i>Liver Cancer</i> , 2015 , 4, 51-69	9.1	35
144	Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma. <i>Cancer</i> , 2015 , 121, 2720-9	6.4	34
143	Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance. <i>British Journal of Cancer</i> , 2017 , 116, 441-447	8.7	32
142	Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization. <i>Radiology</i> , 2014 , 270, 607-20	20.5	31

141	Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma. <i>Liver International</i> , 2017 , 37, 280-289	7.9	28
140	Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 1037-1048	6.1	27
139	Liver stiffness measurement predicts high-grade post-hepatectomy liver failure: A prospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 506-514	4	26
138	PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 539-45	3.5	26
137	Role of alpha-fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both?. <i>Future Oncology</i> , 2009 , 5, 889-99	3.6	26
136	Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars. <i>JCO Global Oncology</i> , 2020 , 6, 1461-1471	3.7	26
135	Impacts of COVID-19 on Liver Cancers: During and after the Pandemic. <i>Liver Cancer</i> , 2020 , 9, 491-502	9.1	26
134	Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data. <i>BMC Cancer</i> , 2017 , 17, 8	4.8	25
133	Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2020 , 26, 4795-4804	12.9	25
132	Microwave ablation provides better survival than liver resection for hepatocellular carcinoma in patients with borderline liver function: application of ALBI score to patient selection. <i>Hpb</i> , 2018 , 20, 546-554	3.8	24
131	KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS503-TPS503	2.2	24
130	A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919889001	5.1	24
129	Detection and characterization of jagged ends of double-stranded DNA in plasma. <i>Genome Research</i> , 2020 , 30, 1144-1153	9.7	23
128	Management of hepatocellular carcinoma: beyond sorafenib. <i>Current Oncology Reports</i> , 2012 , 14, 257-666.3	3	22
127	Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. <i>ESMO Open</i> , 2020 , 5,	6	21
126	Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma. <i>Biochemical Pharmacology</i> , 2012 , 83, 1146-58	6	20
125	KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 209-209	2.2	20
124	Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment. <i>Translational Gastroenterology and Hepatology</i> , 2018 , 3, 89	5.2	20

123	Genome-Wide Screening and Functional Analysis Identifies Tumor Suppressor Long Noncoding RNAs Epigenetically Silenced in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2019 , 79, 1305-1317	10.1	19
122	Novel systemic therapeutic for nasopharyngeal carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2012 , 16 Suppl 1, S63-8	6.4	18
121	International validation of the Chinese university prognostic index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study. <i>Chinese Journal of Cancer</i> , 2014 , 33, 481-91		18
120	Embedding of Genes Using Cancer Gene Expression Data: Biological Relevance and Potential Application on Biomarker Discovery. <i>Frontiers in Genetics</i> , 2018 , 9, 682	4.5	18
119	The ATP-binding cassette transporter ABCF1 is a hepatic oncofetal protein that promotes chemoresistance, EMT and cancer stemness in hepatocellular carcinoma. <i>Cancer Letters</i> , 2019 , 457, 98-109	8.9	17
118	Prospective double-blinded randomized controlled trial of Microwave versus RadioFrequency Ablation for hepatocellular carcinoma (McRFA trial). <i>Hpb</i> , 2020 , 22, 1121-1127	3.8	17
117	Albumin-bilirubin grade predicts the outcomes of liver resection versus radiofrequency ablation for very early/early stage of hepatocellular carcinoma. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2018 , 16, 163-170	2.5	17
116	Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018 , 7, 40-54	9.1	16
115	Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma. <i>International Journal of Hepatology</i> , 2013 , 2013, 103830	2.7	16
114	Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020 , 9, 167-181	9.1	16
113	Steatotic hepatocellular carcinoma: a variant associated with metabolic factors and late tumour relapse. <i>Histopathology</i> , 2016 , 69, 971-984	7.3	15
112	Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study. <i>Liver Cancer</i> , 2021 , 10, 107-114	9.1	15
111	Economic analysis of aprepitant-containing regimen to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Hong Kong. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014 , 10, 80-91	1.9	14
110	Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma. <i>Liver International</i> , 2012 , 32, 271-8	7.9	14
109	Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. <i>Chinese Journal of Cancer</i> , 2014 , 33, 267-76		14
108	Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2020 , 115, 867-875	0.7	13
107	A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma. <i>Cancer</i> , 2017 , 123, 3977-3985	6.4	13
106	Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 1529-35	4	13

105	Randomized phase II trial of intravenous RO5137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma (HCC; NCT01507168).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4102-4102	2.2	13
104	Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 518-518	2.2	13
103	Genome-wide detection of cytosine methylation by single molecule real-time sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	13
102	Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 71, 1417-25	3.5	12
101	Abstract CT106: Ph I/II study of FGF401 in adult pts with HCC or solid tumors characterized by FGFR4/KLB expression 2017 ,		12
100	Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4088-4088	2.2	12
99	Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights. <i>World Journal of Gastroenterology</i> , 2014 , 20, 3135-45	5.6	12
98	Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma		12
97	A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma. <i>Modern Pathology</i> , 2019 , 32, 1646-1656	9.8	11
96	The association of liver function and quality of life of patients with liver cancer. <i>BMC Gastroenterology</i> , 2019 , 19, 66	3	11
95	A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	11
94	A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy (IMRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) with correlation using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). <i>Journal of Clinical Oncology</i> , 2008 , 26, 6055-6055	2.2	10
93	Hepatotoxicity of targeted therapy for cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 789-802	5.5	10
92	Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. <i>JHEP Reports</i> , 2021 , 3, 100215	10.3	10
91	ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib. <i>Cell Death and Disease</i> , 2018 , 9, 852	9.8	10
90	Stereotactic radiotherapy for hepatocellular carcinoma: report of a local single-centre experience. <i>Hong Kong Medical Journal</i> , 2011 , 17, 112-8	0.7	10
89	A concurrent primary hepatic MALT lymphoma and hepatocellular carcinoma. <i>Pathology</i> , 2015 , 47, 178-81.6		9
88	Ectopic HOTTIP expression induces noncanonical transactivation pathways to promote growth and invasiveness in pancreatic ductal adenocarcinoma. <i>Cancer Letters</i> , 2020 , 477, 1-9	9.9	9

87	What do oncologists need to know about biosimilar products?. <i>Chinese Journal of Cancer</i> , 2016 , 35, 91		9
86	Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha. <i>Cancer</i> , 2013 , 119, 4145-53	6.4	9
85	Novel therapeutic targets and predictive markers for hepatocellular carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2015 , 19, 973-83	6.4	8
84	An update on the safety and efficacy of regorafenib in the treatment of solid cancers. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014 , 10, 1607-14	5.5	8
83	Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC. <i>JHEP Reports</i> , 2020 , 2, 100152	10.3	8
82	Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240. <i>Cancer</i> , 2021 , 127, 865-874	6.4	8
81	Correlations of health-related quality of life with serum inflammatory indicators IL-8 and mIBI in patients with hepatocellular carcinoma. <i>Cancer Management and Research</i> , 2019 , 11, 2719-2727	3.6	7
80	Drug development for hepatocellular carcinoma: knowing the past helps to understand the future. <i>Oncologist</i> , 2014 , 19, 1115-7	5.7	7
79	A sensitive and specific liquid chromatography-tandem mass spectrometric method for determination of belinostat in plasma from liver cancer patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010 , 878, 2409-14	3.2	7
78	KEYNOTE-224: Phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS504-TPS504	2.2	7
77	Cell cycle-related kinase reprograms the liver immune microenvironment to promote cancer metastasis. <i>Cellular and Molecular Immunology</i> , 2021 , 18, 1005-1015	15.4	7
76	Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1274-1283	0.7	7
75	Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021 , 10, 510-521	9.1	7
74	Validating the ALBI grade: Its current and future use in HCC prognostication. <i>Journal of Hepatology</i> , 2017 , 66, 661-663	13.4	6
73	Transarterial Ethanol Ablation for Unresectable Hepatocellular Carcinoma: Analysis of Clinical and Tumor Outcomes. <i>Journal of Vascular and Interventional Radiology</i> , 2016 , 27, 639-49	2.4	6
72	Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma. <i>BMC Cancer</i> , 2006 , 6, 259	4.8	6
71	Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4088-4088	2.2	6
70	A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2021 , 39, 1375-1382	4.3	6

69	Impact of Weight Loss During Chemotherapy in Chinese Patients with Unresectable Pancreatic Cancer. <i>Nutrition and Cancer</i> , 2019 , 71, 954-970	2.8	5
68	Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240. <i>Annals of Oncology</i> , 2019 , 30, iv135-iv136	10.3	5
67	Targeting angiogenic genes as a therapeutic approach for hepatocellular carcinoma. <i>Current Gene Therapy</i> , 2015 , 15, 97-108	4.3	5
66	Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS3103-TPS3103	3.3	5
65	Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4020-4020	2.2	5
64	Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 423-423	2.2	5
63	Accomplishments in 2007 in the management of hepatobiliary cancers. <i>Gastrointestinal Cancer Research: GCR</i> , 2008 , 2, S25-31		5
62	Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study. <i>Cancer Medicine</i> , 2020 , 9, 7052-7061	4.8	5
61	Microbiome and cancer treatment: Are we ready to apply in clinics?. <i>Progress in Molecular Biology and Translational Science</i> , 2020 , 171, 301-308	4	4
60	Contaminated and misidentified cell lines commonly use in cancer research. <i>Molecular Carcinogenesis</i> , 2020 , 59, 573-574	5	4
59	Ablative Chemoembolization for Hepatocellular Carcinoma: A Prospective Phase I Case-Control Comparison with Conventional Chemoembolization. <i>Radiology</i> , 2018 , 287, 340-348	20.5	4
58	Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer. <i>Oncologist</i> , 2018 , 23, 1436-1445	5.7	4
57	Phase II study of front-line dovitinib (TKI258) versus sorafenib in patients (Pts) with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 237-237	2.2	4
56	A phase (Ph) II study of the efficacy and safety of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4074-4074	2.2	4
55	Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients. <i>Quality of Life Research</i> , 2019 , 28, 2597-2607	3.7	3
54	6597 POSTER A Phase II Study of Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma [B] Multicenter Study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG). <i>European Journal of Cancer</i> , 2011 , 47, S470-S471	7.5	3
53	An unusual cause of superior vena cava obstruction. <i>Thorax</i> , 2006 , 61, 182	7.3	3
52	Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS4143-TPS4143	2.2	3

51	Efficacy and toxicity of intensity-modulated radiation therapy for prostate cancer in Chinese patients. <i>Hong Kong Medical Journal</i> , 2013 , 19, 407-15	0.7	3
50	Applications of genetic-epigenetic tissue mapping for plasma DNA in prenatal testing, transplantation and oncology. <i>ELife</i> , 2021 , 10,	8.9	3
49	Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study. <i>Annals of Oncology</i> , 2016 , 27, vi241	10.3	3
48	Novel biomarkers GEP/ABCB5 regulate response to adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018 , 17, 524-530	2.1	3
47	Dystrophin-negative slow-twitch soleus muscles are not susceptible to eccentric contraction induced injury over the lifespan of the mouse. <i>American Journal of Physiology - Cell Physiology</i> , 2021 , 321, C704-C720	5.4	3
46	Delayed radiation myelopathy after concurrent chemoradiation for hypopharyngeal-esophageal carcinoma. <i>Acta Oncologica</i> , 2005 , 44, 177-9	3.2	2
45	Therapeutic vaccination with modified vaccinia Ankara (MVA) encoding Epstein-Barr virus (EBV) target antigens in EBV+ nasopharyngeal carcinoma (NPC). <i>Journal of Clinical Oncology</i> , 2008 , 26, 3052-3052	2.2	2
44	Phase I pharmacokinetics and metabolic pathway of belinostat in patients with hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2585-2585	2.2	2
43	A phase I trial of recombinant modified vaccinia ankara (MVA) vaccine encoding Epstein-Barr virus (EBV) antigens.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2592-2592	2.2	2
42	A phase II study of axitinib in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6031-6031	2.2	2
41	Sirtuin 7 super-enhancer drives epigenomic reprogramming in hepatocarcinogenesis. <i>Cancer Letters</i> , 2022 , 525, 115-130	9.9	2
40	Alpha-Fetoprotein as a Biomarker in Hepatocellular Carcinoma: Focus on Its Role in Composition of Tumor Staging Systems and Monitoring of Treatment Response. <i>Biomarkers in Disease</i> , 2017 , 623-635		2
39	Genetic variation in ABCB5 associates with risk of hepatocellular carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020 , 24, 10705-10713	5.6	2
38	ALBI score and outcomes in patients with hepatocellular carcinoma: analysis of the randomized controlled trial KEYNOTE-240. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211039928	5.4	2
37	Single Cell and Plasma RNA Sequencing for RNA Liquid Biopsy for Hepatocellular Carcinoma. <i>Clinical Chemistry</i> , 2021 , 67, 1492-1502	5.5	2
36	Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2021 , 26, 39-52	3.7	2
35	Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas. <i>Gastroenterology</i> , 2020 ,	13.3	1
34	Endoscopic ultrasound-guided cyanoacrylate injection to prevent rebleeding in hepatocellular carcinoma patients with variceal hemorrhage. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 2192-2201	4	1

33	Commentary: the impact of compact lipiodolisation following transarterial chemoembolisation for hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 36, 74-5; discussion 75	6.1	1
32	Prognostic impact of serum alpha-fetoprotein in patients with hepatocellular carcinoma: an international collaborative study. <i>Journal of Hepatology</i> , 2017 , 66, S620-S621	13.4	1
31	Need of stratifying patients according to severity of underlying liver disease for hepatocellular carcinoma patients undergoing systemic therapy trials. <i>Contemporary Clinical Trials</i> , 2010 , 31, 135	2.3	1
30	Reply to L.-T. Chen et al. <i>Journal of Clinical Oncology</i> , 2009 , 27, e272-e272	2.2	1
29	Assessment of liver dysfunction in hepatocellular carcinoma (HCC): An international collaborative study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4094-4094	2.2	1
28	Single-nucleotide polymorphism (SNP) of excision repair cross complementation group 1 (ERCC1) in nasopharynx cancer (NPC): A companion biomarker study to Hong Kong NPC Study Group 0502 trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6029-6029	2.2	1
27	The association between serum folate level and toxicity of capecitabine.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3566-3566	2.2	1
26	A study on thromboembolism of patients with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 262-262	2.2	1
25	RECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 528-528	2.2	1
24	Comparison of Chemoembolization, Radioembolization, and Transarterial Ethanol Ablation for Huge Hepatocellular Carcinoma (≥ 10cm) in Tumour Response and Long-Term Survival Outcome. <i>CardioVascular and Interventional Radiology</i> , 2021 , 1	2.7	1
23	Reply to: "An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously". <i>Journal of Hepatology</i> , 2021 ,	13.4	1
22	The significance of serum interleukin-10 on the outcome of unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2011 , 29, 205-205	2.2	1
21	Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade. <i>JHEP Reports</i> , 2021 , 3, 100224	10.3	1
20	Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.. <i>European Journal of Cancer</i> , 2022 , 167, 1-12	7.5	1
19	Misleading chest radiography in a patient with SARS. <i>Scandinavian Journal of Infectious Diseases</i> , 2004 , 36, 318-20		0
18	Management of Gastrointestinal Side Effects of Immune Checkpoint Inhibitors. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 2262-2265	6.9	0
17	Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: A multinational, multicenter retrospective study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 272-272	2.2	0
16	CircRTN4 promotes pancreatic cancer progression through a novel CircRNA-miRNA-lncRNA pathway and stabilizing epithelial-mesenchymal transition protein.. <i>Molecular Cancer</i> , 2022 , 21, 10	42.1	0

15	Systemic treatment of pancreatic neuroendocrine tumors. <i>Surgical Practice</i> , 2019 , 23, 48-58	0.4
14	Immune Checkpoint Inhibitor-induced Enterocolitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, e70	6.9
13	Development of Serum DHCR24 Antibody as a Marker for Hepatocellular Carcinoma: The End of the Beginning. <i>EBioMedicine</i> , 2015 , 2, 497-8	8.8
12	Re: roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 580	9.7
11	Targeted therapy for hepatocellular carcinoma: current status and future direction. <i>Clinical Investigation</i> , 2013 , 3, 83-93	
10	Initial lenvatinib therapy with no prior TACE in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: A proof-of-concept study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 522-522	2.2
9	A phase II clinical trial on combined axitinib and transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC): Final results and evaluation of clinical predictor for response.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4073-4073	2.2
8	Alpha-Fetoprotein as a Biomarker in Hepatocellular Carcinoma: Focus on Its Role in Composition of Tumor Staging Systems and Monitoring of Treatment Response. <i>Biomarkers in Disease</i> , 2016 , 1-13	
7	Epidemiology of lung cancer: A joinpoint analysis of temporal incidence and mortality trends in 38 countries.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e13091-e13091	2.2
6	A novel and validated inflammation-integrated prognostic model for hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15679-e15679	2.2
5	A randomized study on lipiodal ethanol mixture (LEM) versus transarterial chemoembolization (TACE) for treatment of hepatocellular carcinoma (HCC): Report of a preplanned interim analysis.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14528-e14528	2.2
4	Randomized phase II study of erlotinib (ERL) in two different schedules with concomitant modified XELOX in the first-line treatment of metastatic colorectal cancer (mCRC): Correlation with serial serum levels of amphiregulin (AMR) and transforming growth factor receptor-alpha (TGFA).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4073-4073	2.2
3	A joint United Kingdom (UK) and Hong Kong (HK) study to determine prognostic factors for hepatocellular carcinoma (HCC) undergoing curative and palliative treatment.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 181-181	2.2
2	Comments on "Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients". <i>European Journal of Cancer</i> , 2016 , 68, 203-205	7.5
1	Reply to Comment on "Circulating Neutrophils in patients with hepatocellular carcinoma". <i>British Journal of Cancer</i> , 2018 , 119, 781-782	8.7